BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol 2016;11:115. [PMID: 27600665 DOI: 10.1186/s13014-016-0693-8] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Jiang S, Zhou Y, Zou L, Chu L, Chu X, Ni J, Li Y, Guo T, Yang X, Zhu Z. Low- dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer. Cancer Med 2022. [PMID: 36065943 DOI: 10.1002/cam4.5113] [Reference Citation Analysis]
2 Ruan H, Xiong J. Value of carbon-ion radiotherapy for early stage non-small cell lung cancer. Clin Transl Radiat Oncol 2022;36:16-23. [PMID: 35756194 DOI: 10.1016/j.ctro.2022.06.005] [Reference Citation Analysis]
3 Crous A, Abrahamse H. Photodynamic therapy of lung cancer, where are we? Front Pharmacol 2022;13:932098. [DOI: 10.3389/fphar.2022.932098] [Reference Citation Analysis]
4 Mojdami ZD, Barbour A, Oveisi M, Sun C, Fine N, Saha S, Marks C, Elebyary O, Watson E, Tenenbaum H, Azarpazhooh A, Glogauer M. The Effect of Intensity-Modulated Radiotherapy to the Head and Neck Region on the Oral Innate Immune Response and Oral Microbiome: A Prospective Cohort Study of Head and Neck Tumour Patients. IJMS 2022;23:9594. [DOI: 10.3390/ijms23179594] [Reference Citation Analysis]
5 Garde-Noguera J, Martín-Martín M, Obeso A, López-Mata M, Crespo IR, Pelari-Mici L, Juan Vidal O, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Current treatment landscape for oligometastatic non-small cell lung cancer. World J Clin Oncol 2022; 13(6): 485-495 [DOI: 10.5306/wjco.v13.i6.485] [Reference Citation Analysis]
6 Piletska E, Magumba K, Joseph L, Garcia Cruz A, Norman R, Singh R, Tabasso AFS, Jones DJL, Macip S, Piletsky S. Molecular imprinting as a tool for determining molecular markers: a lung cancer case. RSC Adv 2022;12:17747-54. [PMID: 35765329 DOI: 10.1039/d2ra01830f] [Reference Citation Analysis]
7 Sheikh HS, Munawar K, Sheikh F, Qamar MFU. Lung Cancer in Pakistan. Journal of Thoracic Oncology 2022;17:602-7. [DOI: 10.1016/j.jtho.2022.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Li M, Yang X, Zhang G, Wang L, Zhu Z, Zhang W, Huang H, Gao R. Heterogeneous nuclear ribonucleoprotein K promotes the progression of lung cancer by inhibiting the p53‐dependent signaling pathway. Thoracic Cancer. [DOI: 10.1111/1759-7714.14387] [Reference Citation Analysis]
9 Luo H, Ge H. Application of Proteomics in the Discovery of Radiosensitive Cancer Biomarkers. Front Oncol 2022;12:852791. [PMID: 35280744 DOI: 10.3389/fonc.2022.852791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Senan S, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Murakami S, Hui R, Faivre-Finn C, Paz-Ares L, Wu YL, Mann H, Dennis PA, Antonia SJ. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO Open 2022;7:100410. [PMID: 35247871 DOI: 10.1016/j.esmoop.2022.100410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2021;2:692-729. [PMID: 34977873 DOI: 10.1002/mco2.105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
12 Handa M, Dey M, Saxena A, Beg S, Rahman M, Shukla R. Application of nanotechnology assisted devices in cancer treatment. Nanotherapeutics in Cancer Vaccination and Challenges 2022. [DOI: 10.1016/b978-0-12-823686-4.00004-5] [Reference Citation Analysis]
13 Guo S, Bai X, Shi S, Deng Y, Kang X, An H. TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment. Int J Mol Sci 2021;22:10930. [PMID: 34681590 DOI: 10.3390/ijms222010930] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
14 Fan L, Li B, Li Z, Sun L. Identification of Autophagy Related circRNA-miRNA-mRNA-Subtypes Network With Radiotherapy Responses and Tumor Immune Microenvironment in Non-small Cell Lung Cancer. Front Genet 2021;12:730003. [PMID: 34567080 DOI: 10.3389/fgene.2021.730003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Abe T, Ryuno Y, Iino M, Saito S, Aoshika T, Ohta T, Igari M, Hirai R, Kumazaki Y, Kaira K, Kagamu H, Ishida H, Noda SE, Kato S. A 54 Gy in three fractions of stereotactic body radiotherapy using CyberKnife for T1b-2aN0M0 pathologically confirmed non-small cell lung cancer. Jpn J Clin Oncol 2021:hyab154. [PMID: 34580722 DOI: 10.1093/jjco/hyab154] [Reference Citation Analysis]
16 Ma Q, Geng K, Xiao P, Zeng L. Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer. Biomed Res Int 2021;2021:5963868. [PMID: 34518802 DOI: 10.1155/2021/5963868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Xu JK. Effect of Intensity Modulated Radiotherapy (IMRT) on the immunity, physical status and clinical effect of locally advanced NSCLC patients. Pak J Med Sci 2021;37:1480-5. [PMID: 34475934 DOI: 10.12669/pjms.37.5.4188] [Reference Citation Analysis]
18 Abdelrazzak AB, Hezma AM, El-Bahy GS. ATR-FTIR spectroscopy probing of structural alterations in the cellular membrane of abscopal liver cells. Biochim Biophys Acta Biomembr 2021;1863:183726. [PMID: 34375629 DOI: 10.1016/j.bbamem.2021.183726] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Ying H, Fang M, Hang QQ, Chen Y, Qian X, Chen M. Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-β1/Smad3 pathway. J Cell Mol Med 2021. [PMID: 34327818 DOI: 10.1111/jcmm.16821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
20 Fu W, Zhao J, Hu W, Dai L, Jiang Z, Zhong S, Deng B, Huang Y, Wu W, Yin J. LINC01224/ZNF91 Promote Stem Cell-Like Properties and Drive Radioresistance in Non-Small Cell Lung Cancer. Cancer Manag Res 2021;13:5671-81. [PMID: 34285587 DOI: 10.2147/CMAR.S313744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Liu X, Li KW, Yang R, Geng LS. Review of Deep Learning Based Automatic Segmentation for Lung Cancer Radiotherapy. Front Oncol 2021;11:717039. [PMID: 34336704 DOI: 10.3389/fonc.2021.717039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
22 Chae Y, Roh J, Kim W. The Roles Played by Long Non-Coding RNAs in Glioma Resistance. Int J Mol Sci 2021;22:6834. [PMID: 34202078 DOI: 10.3390/ijms22136834] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Strange CD, Shroff GS, Truong MT, Nguyen QN, Vlahos I, Erasmus JJ. Imaging of the post-radiation chest in lung cancer. Clin Radiol 2021:S0009-9260(21)00253-1. [PMID: 34090709 DOI: 10.1016/j.crad.2021.04.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Lee C, Liu X, Zhang W, Duncan MA, Jiang F, Kim C, Yan X, Teng Y, Wang H, Jiang W, Li Z, Xie J. Ultrasmall Gd@Cdots as a radiosensitizing agent for non-small cell lung cancer. Nanoscale 2021;13:9252-63. [PMID: 33982686 DOI: 10.1039/d0nr08166c] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Ghandourh W, Batumalai V, Boxer M, Holloway L. Can reducing planning safety margins broaden the inclusion criteria for lung stereotactic ablative body radiotherapy? J Med Radiat Sci 2021. [PMID: 33934559 DOI: 10.1002/jmrs.469] [Reference Citation Analysis]
26 Emert F, Missimer J, Eichenberger PA, Walser M, Gmür C, Lomax AJ, Weber DC, Spengler CM. Enhanced Deep-Inspiration Breath Hold Superior to High-Frequency Percussive Ventilation for Respiratory Motion Mitigation: A Physiology-Driven, MRI-Guided Assessment Toward Optimized Lung Cancer Treatment With Proton Therapy. Front Oncol 2021;11:621350. [PMID: 33996545 DOI: 10.3389/fonc.2021.621350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
27 Wang Z, Liu L, Du Y, Mi Y, Wang L. The HNF1A-AS1/miR-92a-3p axis affects the radiosensitivity of non-small cell lung cancer by competitively regulating the JNK pathway. Cell Biol Toxicol 2021. [PMID: 33755848 DOI: 10.1007/s10565-021-09595-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
28 Mistro M, Sheng Y, Ge Y, Kelsey CR, Palta JR, Cai J, Wu Q, Yin FF, Wu QJ. Knowledge Models as Teaching Aid for Training Intensity Modulated Radiation Therapy Planning: A Lung Cancer Case Study. Front Artif Intell 2020;3:66. [PMID: 33733183 DOI: 10.3389/frai.2020.00066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 McGunigal M, Lischalk JW, Randolph-Jackson P, Khaitan PG. Radiation Modalities Used in Lung Cancer: An Overview for Thoracic Surgeons. Semin Thorac Cardiovasc Surg 2021:S1043-0679(21)00103-9. [PMID: 33705939 DOI: 10.1053/j.semtcvs.2021.02.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Saghazadeh A, Keshavarz-fathi M, Delavari F, Rezaei N. Radiation and Immunity: Hand in Hand from Tumorigenesis to Therapeutic Targets. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_30] [Reference Citation Analysis]
31 Li Z, Qu Z, Wang Y, Qin M, Zhang H. miR-101-3p sensitizes non-small cell lung cancer cells to irradiation. Open Med (Wars) 2020;15:413-23. [PMID: 33336000 DOI: 10.1515/med-2020-0044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
32 Yu B, Zhang W, Kwak K, Choi H, Kim DH. Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy. ACS Appl Mater Interfaces 2020;12:54415-25. [PMID: 33237729 DOI: 10.1021/acsami.0c15679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
33 Hao CC, Xu CY, Zhao XY, Luo JN, Wang G, Zhao LH, Ge X, Ge XF. Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the detrimental effect of irradiation on lung adenocarcinoma. J Exp Clin Cancer Res 2020;39:256. [PMID: 33228740 DOI: 10.1186/s13046-020-01772-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
34 Ghandourh W, Dowling J, Chlap P, Oar A, Jacob S, Batumalai V, Holloway L. Assessing tumor centrality in lung stereotactic ablative body radiotherapy (SABR): the effects of variations in bronchial tree delineation and potential for automated methods. Med Dosim 2021;46:94-101. [PMID: 33067108 DOI: 10.1016/j.meddos.2020.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Bakhribah H, Zeitouni M, Daghistani RA, Almaghraby HQ, Khankan AA, Alkattan KM, Alshehri SM, Jazieh AR. Implications of COVID-19 pandemic on lung cancer management: A multidisciplinary perspective. Crit Rev Oncol Hematol 2020;156:103120. [PMID: 33099232 DOI: 10.1016/j.critrevonc.2020.103120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
36 Jie AW, Marignol L. Pro-con of proton: Dosimetric advantages of intensity-modulation over passive scatter for thoracic malignancies. Tech Innov Patient Support Radiat Oncol 2020;15:37-46. [PMID: 32954018 DOI: 10.1016/j.tipsro.2019.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Denman AR, Groves-Kirkby CJ, Crockett RGM. Cost-effectiveness of radon remediation programmes in the UK in the 2020s. J Environ Radioact 2020;222:106351. [PMID: 32892905 DOI: 10.1016/j.jenvrad.2020.106351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sharma A, Almasan A. USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung Cancer. Int J Mol Sci 2020;21:E6383. [PMID: 32887472 DOI: 10.3390/ijms21176383] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
39 Shao J, Wang C, Li J, Song L, Li L, Tian P, Li W. A comprehensive algorithm to distinguish between MPLC and IPM in multiple lung tumors patients. Ann Transl Med 2020;8:1137. [PMID: 33240986 DOI: 10.21037/atm-20-5505] [Reference Citation Analysis]
40 Hatami E, Nagesh PKB, Jaggi M, Chauhan SC, Yallapu MM. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. Eur J Pharmacol 2020;888:173486. [PMID: 32805254 DOI: 10.1016/j.ejphar.2020.173486] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
41 Wang R, Cao Z, Wei L, Bai L, Wang H, Zhou S, Zhan S, Ji B, Li Z, Gao S, Xie J, Ma Q. Barium tungstate nanoparticles to enhance radiation therapy against cancer. Nanomedicine: Nanotechnology, Biology and Medicine 2020;28:102230. [DOI: 10.1016/j.nano.2020.102230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Viani GA, Arruda CV, De Fendi LI. Effectiveness and Safety of Reirradiation With Stereotactic Ablative Radiotherapy of Lung Cancer After a First Course of Thoracic Radiation: A Meta-analysis. Am J Clin Oncol 2020;43:575-81. [PMID: 32554982 DOI: 10.1097/COC.0000000000000709] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
43 Liao ZX, Huang KY, Kempson IM, Li HJ, Tseng SJ, Yang PC. Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer. J Control Release 2020;324:482-92. [PMID: 32497570 DOI: 10.1016/j.jconrel.2020.05.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
44 Bellhouse S, Brown S, Dubec M, Taylor S, Hales R, Whiteside L, Yorke J, Faivre-Finn C. Introducing magnetic resonance imaging into the lung cancer radiotherapy workflow - An assessment of patient experience. Radiography (Lond) 2021;27:14-23. [PMID: 32451307 DOI: 10.1016/j.radi.2020.04.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Pustovalova M, Alhaddad L, Smetanina N, Chigasova A, Blokhina T, Chuprov-Netochin R, Osipov AN, Leonov S. The p53-53BP1-Related Survival of A549 and H1299 Human Lung Cancer Cells after Multifractionated Radiotherapy Demonstrated Different Response to Additional Acute X-ray Exposure. Int J Mol Sci 2020;21:E3342. [PMID: 32397297 DOI: 10.3390/ijms21093342] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
46 Nieder C, Imingen KS, Mannsåker B, Yobuta R, Haukland E. Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer. Radiat Oncol 2020;15:91. [PMID: 32357936 DOI: 10.1186/s13014-020-01550-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Benveniste MF, Gomez D, Carter BW, Betancourt Cuellar SL, Shroff GS, Benveniste APA, Odisio EG, Marom EM. Recognizing Radiation Therapy-related Complications in the Chest. Radiographics 2019;39:344-66. [PMID: 30844346 DOI: 10.1148/rg.2019180061] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 26.0] [Reference Citation Analysis]
48 Liang C, Cao H, Cao X. Tetrandrine can alleviate inflammation and delay the growth of lung cancer during low-dose radiotherapy of non-small cell lung cancer. Biotechnology & Biotechnological Equipment 2020;34:246-53. [DOI: 10.1080/13102818.2020.1736951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Gao S, Zhang W, Wang R, Hopkins SP, Spagnoli JC, Racin M, Bai L, Li L, Jiang W, Yang X, Lee C, Nagata K, Howerth EW, Handa H, Xie J, Ma Q, Kumar A. Nanoparticles Encapsulating Nitrosylated Maytansine To Enhance Radiation Therapy. ACS Nano 2020;14:1468-81. [PMID: 31939662 DOI: 10.1021/acsnano.9b05976] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]
50 Shen T, Sheng L, Chen Y, Cheng L, Du X. High incidence of radiation pneumonitis in lung cancer patients with chronic silicosis treated with radiotherapy. J Radiat Res 2020;61:117-22. [PMID: 31822893 DOI: 10.1093/jrr/rrz084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Chen L, Ren P, Zhang Y, Gong B, Yu D, Sun X. Long non‑coding RNA GAS5 increases the radiosensitivity of A549 cells through interaction with the miR‑21/PTEN/Akt axis. Oncol Rep 2020;43:897-907. [PMID: 32020207 DOI: 10.3892/or.2020.7467] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
52 Pucci P, Yuen W, Venalainen E, Carles DR, Wang Y, Crea F. Long Non-coding RNAs and Cancer Cells’ Drug Resistance: An Unexpected Connection. RNA Technologies 2020. [DOI: 10.1007/978-3-030-44743-4_7] [Reference Citation Analysis]
53 Velez MA, Lisberg A, Suh RD. Primary Lung Cancer. Image-Guided Interventions in Oncology 2020. [DOI: 10.1007/978-3-030-48767-6_4] [Reference Citation Analysis]
54 Zhao Q, Liu M, Wang Z, Huang W, Allen Li X, Zhou T, Zhang J, Zhang Z, Wang Q, Yu S, Han D, Sun H, Li H, Lin H, Li B. High dose radiation therapy based on normal tissue constraints with concurrent chemotherapy achieves promising survival of patients with unresectable stage III non-small cell lung cancer. Radiother Oncol 2020;145:7-12. [PMID: 31869678 DOI: 10.1016/j.radonc.2019.11.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Reda M, Ngamcherdtrakul W, Gu S, Bejan DS, Siriwon N, Gray JW, Yantasee W. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Cancer Lett 2019;467:9-18. [PMID: 31563561 DOI: 10.1016/j.canlet.2019.09.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
56 Sun Z, Liu J, Zhang J, Qian Y. Research Progress of Axl Inhibitors. CTMC 2019;19:1338-49. [DOI: 10.2174/1568026619666190620155613] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
57 Jumeau R, Vilotte F, Durham AD, Ozsahin EM. Current landscape of palliative radiotherapy for non-small-cell lung cancer. Transl Lung Cancer Res 2019;8:S192-201. [PMID: 31673524 DOI: 10.21037/tlcr.2019.08.10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
58 Bavandpour E, Bavandpour M, Karimi Z, Payandeh M, Shakiba E, Dayani M. Safety and Efficacy of Tomotherapy for Lung Cancer Compared to Other Radiotherapy Techniques: A Systematic Review. Health Tech Asmnt Act 2019;2. [DOI: 10.5812/htaa.94241] [Reference Citation Analysis]
59 Li L, Zhang Z, Yang Q, Ning M. Lycorine inhibited the cell growth of non-small cell lung cancer by modulating the miR-186/CDK1 axis. Life Sci 2019;231:116528. [PMID: 31176784 DOI: 10.1016/j.lfs.2019.06.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
60 Van Nest SJ, Nicholson LM, Pavey N, Hindi MN, Brolo AG, Jirasek A, Lum JJ. Raman spectroscopy detects metabolic signatures of radiation response and hypoxic fluctuations in non-small cell lung cancer. BMC Cancer 2019;19:474. [PMID: 31109312 DOI: 10.1186/s12885-019-5686-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
61 Jassem J. Lung cancer: a preventable disease. Transl Lung Cancer Res 2019;8:S1-2. [PMID: 31211099 DOI: 10.21037/tlcr.2019.04.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
62 Rajappa S, Sharma S, Prasad K. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes. Adv Ther 2019;36:563-78. [PMID: 30693419 DOI: 10.1007/s12325-019-0876-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
63 Fraser I, Lefresne S, Regan J, Berthelet E, Chooback N, Ho C, Olson R. Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis. Lung Cancer 2019;135:97-103. [PMID: 31447009 DOI: 10.1016/j.lungcan.2019.02.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
64 Karasawa K, Hayakawa S, Machitori Y, Shibata Y, Ogawa H, Ito K, Shimizuguchi T, Kawamoto T, Nihei K. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up. Technol Cancer Res Treat 2018;17:1533033818806318. [PMID: 30317929 DOI: 10.1177/1533033818806318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
65 Stam B, Kwint M, Guckenberger M, Mantel F, Hope A, Giuliani M, Werner-wasik M, Grills I, Sonke J, Belderbos J. Subgroup Survival Analysis in Stage I-II NSCLC Patients With a Central Tumor Partly Treated With Risk-Adapted SBRT. International Journal of Radiation Oncology*Biology*Physics 2019;103:132-41. [DOI: 10.1016/j.ijrobp.2018.08.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
66 Wirsdörfer F, de Leve S, Jendrossek V. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity? Int J Mol Sci 2018;20:E24. [PMID: 30577587 DOI: 10.3390/ijms20010024] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
67 Guo S, Chen Y, Pang C, Wang X, Shi S, Zhang H, An H, Zhan Y. Matrine is a novel inhibitor of the TMEM16A chloride channel with antilung adenocarcinoma effects. J Cell Physiol 2019;234:8698-708. [PMID: 30370542 DOI: 10.1002/jcp.27529] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 12.5] [Reference Citation Analysis]
68 Chung CK, Da Silva C, Kralisch D, Chan A, Ossendorp F, Cruz LJ. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences. Journal of Controlled Release 2018;285:56-66. [DOI: 10.1016/j.jconrel.2018.07.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
69 Grass GD, Naghavi AO, Abuodeh YA, Perez BA, Dilling TJ. Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer 2019;20:e1-7. [PMID: 30268836 DOI: 10.1016/j.cllc.2018.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
70 Tekatli H, Spoelstra FOB, Palacios M, van Sornsen de Koste J, Slotman BJ, Senan S. Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches. Lung Cancer 2018;123:142-8. [PMID: 30089586 DOI: 10.1016/j.lungcan.2018.07.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
71 Yang N, Yao S, Liu D. Tumor necrosis factor-related apoptosis-inducing ligand additive with Iodine-131 of inhibits non-small cell lung cancer cells through promoting apoptosis. Oncol Lett 2018;16:276-84. [PMID: 29928412 DOI: 10.3892/ol.2018.8635] [Reference Citation Analysis]
72 Blasco AS, Cortes CV, Arcuch VS, Letelier RB, Caprio SB. Radiation Therapy for Non-Small Cell Lung Cancer in the Twenty-First Century. Cancer Management and Therapy 2018. [DOI: 10.5772/intechopen.76513] [Reference Citation Analysis]
73 Benveniste MF, Gomez D, Viswanathan C, Shroff GS, Betancourt Cuellar SL, Carter BW, Marom EM. Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. J Thorac Imaging 2017;32:288-99. [PMID: 28832415 DOI: 10.1097/RTI.0000000000000293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Benveniste MF, Welsh J, Viswanathan C, Shroff GS, Betancourt Cuellar SL, Carter BW, Marom EM. Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. Radiol Clin North Am 2018;56:471-83. [PMID: 29622079 DOI: 10.1016/j.rcl.2018.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
75 Kageyama SI, Nihei K, Karasawa K, Sawada T, Koizumi F, Yamaguchi S, Kato S, Hojo H, Motegi A, Tsuchihara K, Akimoto T. Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. Oncotarget 2018;9:19368-78. [PMID: 29721209 DOI: 10.18632/oncotarget.25053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
76 Murrell DH, Laba JM, Erickson A, Millman B, Palma DA, Louie AV. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk? Radiat Oncol 2018;13:57. [PMID: 29606150 DOI: 10.1186/s13014-018-1001-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
77 Tini P, Nardone V, Pastina P, Pirtoli L, Correale P, Giordano A. The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer. Expert Rev Anticancer Ther 2018;18:593-602. [PMID: 29582686 DOI: 10.1080/14737140.2018.1458615] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
78 Benveniste MF, Betancourt Cuellar SL, Gomez D, Shroff GS, Carter BW, Benveniste APA, Marom EM. Imaging of Radiation Treatment of Lung Cancer. Semin Ultrasound CT MR 2018;39:297-307. [PMID: 29807640 DOI: 10.1053/j.sult.2018.02.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
79 Kordbacheh T, Honeychurch J, Blackhall F, Faivre-finn C, Illidge T. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. Annals of Oncology 2018;29:301-10. [DOI: 10.1093/annonc/mdx790] [Cited by in Crossref: 60] [Cited by in F6Publishing: 70] [Article Influence: 15.0] [Reference Citation Analysis]
80 Dhont J, Vandemeulebroucke J, Burghelea M, Poels K, Depuydt T, Van Den Begin R, Jaudet C, Collen C, Engels B, Reynders T, Boussaer M, Gevaert T, De Ridder M, Verellen D. The long- and short-term variability of breathing induced tumor motion in lung and liver over the course of a radiotherapy treatment. Radiotherapy and Oncology 2018;126:339-46. [DOI: 10.1016/j.radonc.2017.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 15.5] [Reference Citation Analysis]
81 Dilnawaz F, Sahoo SK. Augmented Anticancer Efficacy by si-RNA Complexed Drug-Loaded Mesoporous Silica Nanoparticles in Lung Cancer Therapy. ACS Appl Nano Mater 2018;1:730-40. [DOI: 10.1021/acsanm.7b00196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
82 Iijima M, Gombodorj N, Tachibana Y, Tachibana K, Yokobori T, Honma K, Nakano T, Asao T, Kuwahara R, Aoyama K, Yasuda H, Kelly M, Kuwano H, Yamanouchi D. Development of single nanometer-sized ultrafine oxygen bubbles to overcome the hypoxia-induced resistance to radiation therapy via the suppression of hypoxia-inducible factor‑1α. Int J Oncol 2018;52:679-86. [PMID: 29393397 DOI: 10.3892/ijo.2018.4248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
83 Han C, Schultheiss TE, Wong JYC. Comparison of Stereotactic Body Radiotherapy Delivery Techniques for Early-Stage Lung Cancer Using Lung Toxicity Modeling. IJMPCERO 2018;07:1-14. [DOI: 10.4236/ijmpcero.2018.71001] [Reference Citation Analysis]
84 Tu CY, Hsia TC, Fang HY, Liang JA, Yang ST, Li CC, Chien CR. A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients. Radiol Oncol 2018;52:181-8. [PMID: 30018522 DOI: 10.1515/raon-2017-0058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
85 De Ruysscher D, Lambrecht M, van Baardwijk A, Peeters S, Reymen B, Verhoeven K, Wanders R, Öllers M, van Elmpt W, van Loon J. Standard of care in high-dose radiotherapy for localized non-small cell lung cancer. Acta Oncol 2017;56:1610-3. [PMID: 28840754 DOI: 10.1080/0284186X.2017.1349337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
86 Kwint M, Walraven I, Burgers S, Hartemink K, Klomp H, Knegjens J, Verheij M, Belderbos J. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. Lung Cancer 2017;112:134-9. [DOI: 10.1016/j.lungcan.2017.08.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
87 Alongi F, Giaj-Levra N, Sciascia S, Fozza A, Fersino S, Fiorentino A, Mazzola R, Ricchetti F, Buglione M, Buonfrate D, Roccatello D, Ricardi U, Bisoffi Z. Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncol 2017;18:e379-93. [PMID: 28677574 DOI: 10.1016/S1470-2045(17)30440-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
88 Miyakawa A, Shibamoto Y, Baba F, Manabe Y, Murai T, Sugie C, Yanagi T, Takaoka T. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study. Radiat Oncol. 2017;12:152. [PMID: 28893300 DOI: 10.1186/s13014-017-0888-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
89 Nieder C. Einfluss von Dosis und Fraktionierung auf die kurativ intendierte Strahlentherapie. Info Onkol 2017;20:26-27. [DOI: 10.1007/s15004-017-5740-6] [Reference Citation Analysis]
90 Vachani A, Sequist LV, Spira A. AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. Am J Respir Crit Care Med 2017;195:1150-60. [PMID: 28459327 DOI: 10.1164/rccm.201702-0433CI] [Cited by in Crossref: 56] [Cited by in F6Publishing: 63] [Article Influence: 11.2] [Reference Citation Analysis]
91 Pezzuto A, Terzo F, Graziani ML, Ricci A, Bruno P, Mariotta S. Lung cancer requires multidisciplinary treatment to improve patient survival: A case report. Oncol Lett 2017;14:3035-8. [PMID: 28928841 DOI: 10.3892/ol.2017.6511] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
92 Weiss E. Long-Term Safety and Stability of Gold Coil Fiducial Markers in Non-Small-Cell Lung Cancer Image-Guided Radiotherapy. IJRRT 2017;3. [DOI: 10.15406/ijrrt.2017.03.00049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
93 Jiang X, Zhang QL, Tian YH, Huang JC, Ma GL. RNA interference-mediated gene silencing of cyclophilin A enhances the radiosensitivity of PAa human lung adenocarcinoma cells in vitro. Oncol Lett 2017;13:1619-24. [PMID: 28454299 DOI: 10.3892/ol.2017.5667] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
94 Nieder C. [Influence of dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer]. Strahlenther Onkol 2017;193:240-2. [PMID: 28120007 DOI: 10.1007/s00066-017-1096-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
95 Ricardi U, Badellino S, Filippi AR. What do radiation oncologists require for future advancements in lung SBRT? Phys Med 2017;44:150-6. [PMID: 27914779 DOI: 10.1016/j.ejmp.2016.11.114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]